- $438.66m
- $445.98m
- $99.99m
NeuroPace, Inc. reports results for the quarter ended June 30 - Earnings Summary
NeuroPace Q2 revenue slightly beats estimates
Brief: NeuroPace, Inc. Q2 EPS USD -0.18
NeuroPace, Inc. expected to post a loss of 21 cents a share - Earnings Preview
Brief: Neuropace Receives FDA Guidance On Pma Supplement For Indication Expansion Into Idiopathic Generalized Epilepsy
NeuroPace Q1 revenue rises 20%, beats estimates, raises 2026 outlook
Brief: NeuroPace, Inc. Q1 EPS USD -0.2
NeuroPace Q4 revenue rises
Brief: Neuropace Files Pma Supplement To FDA
Brief: Neuropace Announces Positive 18-Month NAUTILUS Trial Results In Idiopathic Generalized Epilepsy
U.S. STOCKS ON THE MOVE-Merck, Genco, Tesla
U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP Materials
NeuroPace jumps as Medicare boosts pay for epilepsy device procedures
NeuroPace's Q3 revenue beats estimates
Brief: NeuroPace, Inc. Q3 EPS USD -0.11
Neuropace Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: NeuroPace, Inc. Q2 EPS USD -0.26
Neuropace Inc expected to post a loss of 22 cents a share - Earnings Preview